The performance of companies tied to Sildenafil's past presents a intricate investment picture . While the initial surge generated substantial gains, generic alternatives have significantly diminished market share . Investing in associated pharmaceutical businesses now requires a careful assessment of proprietary rights , evolving healthcare trends